Compare iShares International Treasury Bond ETF (IGOV) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Repligen Corporation Common Stock — how do they compare? iShares International Treasury Bond ETF trades at $39.67 (market cap $1.31B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 8.6× iShares International Treasury Bond ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Repligen Corporation Common Stock for 0 Days on average.
| IGOV | RGEN | |
|---|---|---|
Market Cap | $1.31B | $11.31B |
Volume | 69,817 | 1,216,919 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $194.57 |
52-Week Low | $39.58 | $102.87 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.79, up 0.53% with mixed technical signals showing bearish moving averages but bullish oscillators. The stock faces resistance at $40-$42 while finding support near $39. Financial ratios remain unavailable, requiring deeper fundamental analysis to assess valuation and profitability metrics.
The stock's outlook remains uncertain with technical indicators conflicting and limited fundamental data available. Rising bond yields create macroeconomic headwinds for equities, though inverse Treasury ETF opportunities mentioned in recent news could signal defensive positioning. Investors need updated financial disclosures to properly evaluate investment merit.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
